

Drug Utilization Review Board
(DUR Board)
Meeting – August 13, 2008 @ 6:00 p.m.

Oklahoma Health Care Authority
4545 N. Lincoln Suite 124
Oklahoma City, Oklahoma 73105
Oklahoma Health Care Authority Board Room

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Meece, Vice-Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Meece, Vice-Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. Meece, Vice-Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. July 9, 2008 DUR Minutes – Vote
 - B. July 10, 2008 DUR Recommendations Memorandum
 - C. Provider Correspondence

Items to be presented by Dr. Keast, Dr. Meece, Vice-Chairman:

- 4. Update on DUR/MCAU Program – See Appendix B.**
 - A. Retrospective Drug Utilization Review for April 2008
 - B. Retrospective Drug Utilization Review Responses for January 2008
 - C. Medication Coverage Activity Audit for July 2008
 - D. Help Desk Activity Audit for July 2008

Items to be presented by Dr. Patel, Dr. Meece, Vice-Chairman

- 5. Action Item – Vote to Prior Authorize Voltaren[®] Gel – See Appendix C.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Keast, Dr. Meece, Vice-Chairman:

6. **30 Day Notice to Prior Authorize Erythropoiesis Stimulating Agents – See Appendix D.**
 - A. Product Information
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Browning, Dr. Meece, Vice-Chairman

7. **30 Day Notice to Prior Authorize Patanase[®] – See Appendix E.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Moore, Dr. Meece, Vice-Chairman

8. **Action Item – Annual Review of Antiulcer PBPA Category and 30 Day Notice to Prior Authorize Protonix[®] Suspension – See Appendix F.**
 - A. Current PA Criteria
 - B. Utilization Review
 - C. COP Recommendations

Items to be presented by Dr. Patel, Dr. Meece, Vice-Chairman

9. **Action Item – Quaaliquin[®] Annual Review – See Appendix G.**
 - A. Product Summary
 - B. Current PA Criteria
 - C. Utilization Review
 - D. COP Recommendations

Items to be presented by Dr. Le, Dr. Meece, Vice-Chairman

10. **White Paper on Bioequivalent Medications – See Appendix H.**
 - A. White Paper
 - B. FDA MedWatch Form

Items to be presented by Dr. Graham, Dr. Meece, Vice-Chairman

11. **FDA and DEA Updates – See Appendix I.**
12. **Future Business**
 - A. Antidepressants
 - B. Oral Antifungals Utilization Review
 - C. Hemophilia Review
 - D. Annual Reviews
 - F. Glaucoma Intervention Report
 - G. New Product Reviews
13. **Adjournment**